Quest Diagnostics has completed its previously announced acquisition of Cleveland HeartLab. Quest will establish a national center of excellence focused on heart disease diagnostics within Cleveland HeartLab's existing 25,000 square-foot clinical laboratory facility in Cleveland.
The acquisition combines the expertise of Cleveland HeartLab's personalized evaluation of heart disease risk based on inflammation and other markers with Quest's Cardio IQ lipid particle analysis and genetic and metabolic testing leadership. Heart disease is the number one cause of death in the United States. Conventional laboratory tests to assess cardiovascular disease, such as cholesterol panels, may not identify risk in all patients. New inflammation, genetic and other biomarkers may help physicians identify at-risk patients and guide treatment protocols to improve outcomes.
"Heart disease is often preventable, but too often patients don't realize they are at risk until it is too late," said Steve Rusckowski, chairman, president and chief executive officer, Quest Diagnostics. "Joining together with Cleveland HeartLab will expand access to cardiometabolic diagnostic innovations that can help patients identify their personal risk and achieve the best possible health outcomes. It supports our strategy to accelerate growth while also helping more patients gain the insights they need to lead healthier lives."
In connection with the acquisition, Quest Diagnostics and Cleveland Clinic have also finalized a strategic collaboration intended to speed the commercialization of emerging innovations at Cleveland Clinic, including its Lerner Research Institute. The two entities also intend to collaborate on trials to demonstrate the clinical and economic value of these and other biomarkers.
Quest diagnostics, completes acquisition, cleveland heartlab
4.jpg)
